Trial Profile
Efficacy of quadrivalent human papillomavirus vaccine (Gardasil) for recurrent respiratory papillomatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 28 Jun 2019 Status changed from recruiting to completed.
- 24 May 2016 New trial record